Pharmicell
CompanySouth Korea
Pharmicell Co., Ltd. develops 2 assets, the furthest in phase 2 (cellgram-spine in spinal cord injury). Mostly cell therapy acting on stem cell maintenance and inflammation; based in South Korea.
- Assets
- 2
- Furthest
- Phase 2
- Trials
- 1
- Signals
- 0
Pipeline
2Autologous bone marrow-derived mesenchymal stem cell therapy for spinal cord injury repair.
Phase 2Cell therapyStem cell maintenancespinal cord injury
Umbilical cord-derived mesenchymal stem cells for tissue repair and immunomodulation
Phase 2Cell therapyInflammationStem cell maintenanceCOVID-19 pneumoniaHuntington's disease
Full company profiles: pipeline, trials, funding and people.
See Pro- Evidence behind the mechanisms3
- Trials1
- Signals2
- Similar companies6
Updated 7 Oct 2026 · 30 sources